How much is Tyra Biosciences worth in 2026?

Tyra Biosciences has a current valuation of N/A based on their PIPE round and secondary market data.

How much funding has Tyra Biosciences raised?

Tyra Biosciences has raised N/A in total funding across 1 funding rounds.

Tyra Biosciences

Drug Discovery

Tyra Biosciences valuation and funding history | Last updated: February 6, 2024 | 1 funding rounds

Current Valuation

N/A

As of February 6, 2024

Total Funding Raised

N/A

Across 1 round

Last Round

PIPE

$200.0M

Last Funding

Feb 2024

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
February 6, 2024	PIPE	$200.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Tyra Biosciences is currently valued at N/A as of February 6, 2024.

Track Tyra Biosciences Valuation Updates

Get notified when Tyra Biosciences raises new funding or valuation changes

Explore More Data

Detailed analysis for Tyra Biosciences

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Tyra Biosciences's valuation history, funding rounds, and growth metrics.

No credit card required

What is Tyra Biosciences Worth in 2026?

Tyra Biosciences is a leading private company in the Drug Discovery sector. Track Tyra Biosciences's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Tyra Biosciences Valuation is Determined

Private company valuations like Tyra Biosciences's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.